Dupilumab + Placebo + Fexofenadine (loratadine if not available)
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pruritus
Conditions
Pruritus
Trial Timeline
Feb 15, 2022 → Aug 25, 2027
NCT ID
NCT05263206About Dupilumab + Placebo + Fexofenadine (loratadine if not available)
Dupilumab + Placebo + Fexofenadine (loratadine if not available) is a phase 3 stage product being developed by Sanofi for Pruritus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05263206. Target conditions include Pruritus.
What happened to similar drugs?
0 of 5 similar drugs in Pruritus were approved
Approved (0) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05263206 | Phase 3 | Recruiting |
Competing Products
20 competing products in Pruritus